Thursday, 23 January 2020 10:26

Fonterra offloads DFE Pharma, bags $550m

Written by  Sudesh Kissun
Fonterra chief financial officer Marc Rivers. Fonterra chief financial officer Marc Rivers.

Fonterra is receiving a $550 million cash boost following the sale of its 50% stake in pharmaceutical maker, DFE Pharma.

And the co-op is signalling more “one-off” transactions this year as it grapples to strengthen its balance sheet following two straight years of net losses.

The DFE Pharma sale, first announced in September 2019, has completed regulatory approvals from competition authorities.

Fonterra chief financial officer Marc Rivers says the completion of this sale is a key milestone in strengthening the co-op’s balance sheet, with cash proceeds of $554 million, comprising of the original sale proceeds of $537 million plus $17 million in settlement adjustments.

Over the course of the 2020 financial year Fonterra expects there to be other one-off transactions as it implements strategy and continues its asset portfolio review, he adds.

Rivers says it’s too early to comment on the impact of asset sales on the 2020 financial year.

“The announced forecast earnings range will continue to reflect just the underlying performance of the business. 

“We will provide details of the overall impact of all one-offs as part of our full-year financial statements and will also provide an update as part of our Interim Results,” Rivers says.

DFE Pharma was a joint venture established in 2006 between Fonterra and Dutch-based FrieslandCampina. DFE Pharma is one of the largest suppliers of pharmaceutical bulking agents in medicines such as tablets and powder inhalers.

DFE Pharma has production locations in Europe, India and New Zealand (Kapuni). 

More like this

A great outcome - Hurrell

Fonterra chief executive Miles Hurrell says the sale of the co-op’s consumer and associated businesses to Lactalis represents a great outcome for the co-op.

Featured

Manuka honey trader posts sour results

Manuka honey trader Comvita slumped to a $104 million net loss last financial year, reflecting prolonged market disruption, oversupply and pricing volatility.

Poultry industry, Govt sign landmark biosecurity deal

The Government has struck a deal with New Zealand's poultry industry, agreeing how they will jointly prepare for and respond to exotic poultry diseases, including any possible outbreak of high pathogenicity avian influenza (HPAI).

National

Machinery & Products

» Latest Print Issues Online

Milking It

Dreams aren't plans

OPINION: Milking It reckons if you're National, looking at recent polls, the dream scenario is that the elusive economic recovery…

Fatberg

OPINION: Sydney has a $12 million milk disposal problem.

» Connect with Dairy News

» eNewsletter

Subscribe to our weekly newsletter